<DOC>
	<DOCNO>NCT02667938</DOCNO>
	<brief_summary>The main objective study evaluate efficacy safety HCP1301 capsule patient Benign Prostatic Hyperplasia Erectile Dysfunction</brief_summary>
	<brief_title>A Phase 3 Clinical Trial Evaluate Efficacy Safety HCP1303 Capsules</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , phase 3 clinical trial evaluate efficacy safety HCP1303 capsule</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>At Visit 1 1 . ≥50 age 2 . BPH ( Benign Prostatic Hyperplasia ) + Total IPSS ( International Prostate Symptom Score ) ≥ 13 3 . Abnormal Erectile function ≥ least 3months base screening date At Visit 2 1 . Total IPSS ≥ 13 1 . History hypersensitivity Tamsulosin Tadalafil 2 . History allergy Sulfonamide 3 . PSA ( Prostate Specific Antigen ) ≥4ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>